Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Scientifica (Cairo) ; 2020: 5019607, 2020.
Article in English | MEDLINE | ID: mdl-33381354

ABSTRACT

Publishing original peer-reviewed research is essential for advancement through all career stages. Fewer women than men hold senior-level positions in academic medicine and, therefore, examining publication trends relative to gender is important. The goal of this study was to examine and compare publication trends in The Journal of Bone and Joint Surgery (JBJS) and The Bone and Joint Journal (BJJ) with a particular emphasis on trends regarding author gender. Data was collected and analyzed for manuscripts published in JBJS and BJJ over the past 30 years. For manuscripts published in 1986, 1996, 2006, and 2016, we recorded the numbers of authors, manuscript pages, references, collaborating institutions, the position in the byline of the corresponding author, the country of the corresponding author, and the names of the first and corresponding author. We also calculated the normalized number of citations and corresponding author position. The number of authors, institutions, and countries collaborating on manuscripts published in both JBJS and BJJ increased over time. JBJS published more manuscripts from North America and BJJ published more manuscripts from Europe. In both journals, the percentage of women as first and/or corresponding author increased over time. Trends over the past 30 years have shown increased collaborations with greater citations in manuscripts published in JBJS and BJJ. In the same time period, both journals demonstrated a rise in the percentage of manuscripts with women first and/or corresponding authors, suggesting a decrease in the gender gap.

2.
J Card Surg ; 35(10): 2704-2709, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32720357

ABSTRACT

PURPOSE: The effect of preoperative cardiac troponin level on outcomes after coronary artery bypass grafting (CABG) is unclear. We investigated the impact of preoperative cardiac troponin I (cTnI) level as well as the time interval between maximum cTnI and surgery on CABG outcomes. METHODS: All patients who underwent isolated CABG at our institution between 2009 and 2016 and had preoperative cTnI level available were identified using our Society of Thoracic Surgeons registry. Receiver operating characteristic (ROC) analysis was performed to identify a cTnI threshold level. Subjects were divided into groups based on this value and outcomes compared. RESULTS: A total of 608 patients were included. ROC analysis identified 5.74 µg/dL as the threshold value associated with worse postoperative outcomes. Patients with peak cTnI >5.74 µg/dL underwent CABG approximately 1 day later, had twice the risk of adverse postoperative events, and had 2.8 day longer postoperative length of stay than those with peak cTnI ≤5.74 µg/dL. cTnI level was not associated with mortality or 30-day readmission. Time interval between peak cTnI and surgery did not affect outcomes. CONCLUSION: Elevated preoperative cTnI level beyond a certain threshold value is associated with adverse postoperative outcomes but is not a marker for increased mortality. Time from peak cTnI does not affect postoperative outcomes or mortality and may not need to be considered when deciding timing of CABG.


Subject(s)
Coronary Artery Bypass , Negative Results , Troponin I/blood , Aged , Biomarkers/blood , Coronary Artery Bypass/adverse effects , Coronary Artery Bypass/mortality , Coronary Artery Disease/surgery , Female , Humans , Male , Middle Aged , Predictive Value of Tests , Preoperative Period , ROC Curve , Treatment Outcome
3.
Ann Thorac Cardiovasc Surg ; 26(2): 65-71, 2020 Apr 20.
Article in English | MEDLINE | ID: mdl-31588070

ABSTRACT

PURPOSE: Acute pulmonary embolism (PE) remains a significant cause of morbidity and requires prompt diagnosis and management. While non-surgical approaches have supplanted surgery as primary treatment, surgical pulmonary embolectomy (SPE) remains a vital option for select patients. We review the current management of acute PE, with a focus on surgical therapy. METHODS: A PubMed search was performed to identify literature regarding PE and treatment. Results were filtered to include the most comprehensive publications over the past decade. RESULTS: PE is stratified based on presenting hemodynamic status or degree of mechanical pulmonary arterial occlusion. Although systemic or catheter-guided fibrinolysis is the preferred first-line treatment for the majority of cases, patients who are not candidates should be considered for SPE. Studies demonstrate no mortality benefit of thrombolysis over surgery. Systemic anticoagulation is a mainstay of treatment regardless of intervention approach. Following surgical embolectomy, direct oral anticoagulants (DOACs) have been shown to reduce recurrence of thromboembolism. CONCLUSIONS: Acute PE presents with varying degrees of clinical stability. Patients should be evaluated in the context of various available treatment options including medical, catheter-based, and surgical interventions. SPE is a safe and appropriate treatment option for appropriate patients.


Subject(s)
Anticoagulants/administration & dosage , Embolectomy , Pulmonary Embolism/therapy , Thrombolytic Therapy , Acute Disease , Anticoagulants/adverse effects , Embolectomy/adverse effects , Embolectomy/mortality , Hemodynamics , Humans , Pulmonary Embolism/diagnostic imaging , Pulmonary Embolism/mortality , Pulmonary Embolism/physiopathology , Recurrence , Risk Factors , Thrombolytic Therapy/adverse effects , Thrombolytic Therapy/mortality , Treatment Outcome
4.
ACS Chem Biol ; 13(8): 2288-2299, 2018 08 17.
Article in English | MEDLINE | ID: mdl-29893552

ABSTRACT

Genetic and epigenetic alterations in FK506-binding protein 5 ( FKBP5) have been associated with increased risk for psychiatric disorders, including post-traumatic stress disorder (PTSD). Some of these common variants can increase the expression of FKBP5, the gene that encodes FKBP51. Excess FKBP51 promotes hypothalamic-pituitary-adrenal (HPA) axis dysregulation through altered glucocorticoid receptor (GR) signaling. Thus, we hypothesized that GR activity could be restored by perturbing FKBP51. Here, we screened 1280 pharmacologically active compounds and identified three compounds that rescued FKBP51-mediated suppression of GR activity without directly activating GR. One of the three compounds, benztropine mesylate, disrupted the association of FKBP51 with the GR/Hsp90 complex in vitro. Moreover, we show that removal of FKBP51 from this complex by benztropine restored GR localization in ex vivo brain slices and primary neurons from mice. In conclusion, we have identified a novel disruptor of the FKBP51/GR/Hsp90 complex. Targeting this complex may be a viable approach to developing treatments for disorders related to aberrant FKBP51 expression.


Subject(s)
Benztropine/pharmacology , Depression/drug therapy , HSP90 Heat-Shock Proteins/metabolism , Receptors, Glucocorticoid/metabolism , Stress Disorders, Post-Traumatic/drug therapy , Tacrolimus Binding Proteins/metabolism , Animals , Benztropine/chemistry , Brain/drug effects , Brain/metabolism , Cells, Cultured , Depression/metabolism , Drug Discovery , Humans , Mice , Molecular Targeted Therapy , Protein Binding/drug effects , Stress Disorders, Post-Traumatic/metabolism , Tacrolimus Binding Proteins/antagonists & inhibitors
5.
Cell Mol Life Sci ; 72(10): 1863-79, 2015 May.
Article in English | MEDLINE | ID: mdl-25666877

ABSTRACT

Pathological accumulation of the microtubule-associated protein tau, in the form of neurofibrillary tangles, is a major hallmark of Alzheimer's disease, the most prevalent neurodegenerative condition worldwide. In addition to Alzheimer's disease, a number of neurodegenerative diseases, called tauopathies, are characterized by the accumulation of aggregated tau in a variety of brain regions. While tau normally plays an important role in stabilizing the microtubule network of the cytoskeleton, its dissociation from microtubules and eventual aggregation into pathological deposits is an area of intense focus for therapeutic development. Here we discuss the known cellular factors that affect tau aggregation, from post-translational modifications to molecular chaperones.


Subject(s)
Alzheimer Disease/physiopathology , Heat-Shock Proteins/metabolism , Molecular Chaperones/metabolism , Protein Aggregation, Pathological/metabolism , tau Proteins/metabolism , Acetylation , Glycosylation , Humans , Microtubules/metabolism , Phosphorylation , Proteolysis , tau Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...